On October 14, 2025, GeneDx announced its involvement in the Sunshine Genetics Act through a partnership with Florida’s Sunshine Genetics Network, marking the launch of the nation’s first state‑backed genomic newborn screening program. The announcement was made from GAITHERSBURG, Md., and released via Business Wire. This partnership positions GeneDx at the forefront of a new public health initiative that integrates genomic testing into state newborn screening protocols.
The program represents a significant milestone for both Florida and the broader newborn screening community, as it is the first program in the United States to receive state backing for genomic sequencing. By participating in this initiative, GeneDx will play a key role in providing the genomic testing infrastructure and expertise required to screen newborns for a range of genetic conditions. This move expands GeneDx’s reach into a large, state‑funded population and underscores its leadership in genomic diagnostics.
From a business perspective, the partnership opens a new revenue stream for GeneDx and strengthens its position in the rapidly growing newborn screening market. It also enhances the company’s regulatory footprint, demonstrating its ability to navigate state‑level health initiatives and comply with public health mandates. The collaboration is expected to accelerate GeneDx’s growth trajectory and solidify its role as a primary provider of genomic testing services in the United States.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.